Clinical Trials Logo

Clinical Trial Summary

Previous multi-dose Phase I and Phase II clinical studies have demonstrated that ADSTILADRIN is a safe and effective treatment for BCG-refractory and recurrent NMIBC. This Phase III study is designed to expand those observations using a high dose of ADSTILADRIN in patients that are "BCG Unresponsive" which refers to patients with high-grade NMIBC who are unlikely to benefit from and should not receive further intravesical BCG.


Clinical Trial Description

Recombinant IFN alpha2b has pleiotropic effects that contribute to antitumor activity in Non-Muscle Invasive Bladder Cancer (NMIBC). ADSTILADRIN is a non-replicating adenovirus vector harboring the human IFN alpha2b gene. When combined with the excipient Syn3, intravesical administration of the rAd-IFN results in transduction of the virus into the epithelial cell lining in the bladder. The IFN alpha2b gene is incorporated into the cellular DNA resulting in the synthesis and expression of large amounts of IFN alpha2b protein. Clinical studies have confirmed that IFN alpha2b protein can be measured in the urine of patients treated with ADSTILADRIN within 24 hours after dosing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02773849
Study type Interventional
Source Ferring Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date September 19, 2016
Completion date May 24, 2023

See also
  Status Clinical Trial Phase
Completed NCT01687244 - Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer Phase 2
Recruiting NCT03379909 - Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer Phase 2
Completed NCT00782587 - Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer Phase 1
Recruiting NCT05084586 - Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation N/A
Recruiting NCT03121768 - A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) N/A
Completed NCT03091764 - Evaluation of a Patient-Reported Symptom Index for NMIBC
Completed NCT01939756 - Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms Phase 1/Phase 2
Completed NCT00595088 - Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer Phase 2
Completed NCT02007005 - Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer Phase 1/Phase 2
Completed NCT01149174 - Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer Phase 3
Completed NCT00322699 - Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer Phase 1/Phase 2
Completed NCT00191711 - Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. Phase 2
Completed NCT00192049 - A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer Phase 2
Recruiting NCT04752722 - LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve Phase 1/Phase 2
Recruiting NCT02106572 - Therapeutic Instillation of Mistletoe Phase 3
Completed NCT00734994 - Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer Phase 0